Healthrelated quality of life from the MM003 trial

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus highdose dexamethasone in relapsed and/or refractory multiple myeloma by Kevin W. Song, Meletios A. Dimopoulos, Katja C. Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternas, Xin Yu, Ramesh Amatya, Mara S. Monzini, Mohamed Zaki, Christian Jacques, and Jesus San Miguel haematol Volume 100(2): e 63 -e 67 January 31, 2015 © 2015 by Ferrata Storti Foundation

Trial design. a. Progression of disease was independently adjudicated in real time. b. Hi. DEX was chosen as comparator because at the time of trial design it was the standard salvage therapy for heavily pre-treated patients. Kevin W. Song et al. Haematologica 2015; 100: e 63 -e 67 © 2015 by Ferrata Storti Foundation

Cross-sectional analysis of mean HRQo. L score changes from baseline per treatment cycle. *P<0. 05 unpaired t-test comparing the two treatment groups from baseline; ‡P<0. 05 paired t-test (within group mean change from baseline). Kevin W. Song et al. Haematologica 2015; 100: e 63 -e 67 © 2015 by Ferrata Storti Foundation

Repeated measure mixed model score changes from baseline (adjusted means). Kevin W. Song et al. Haematologica 2015; 100: e 63 -e 67 © 2015 by Ferrata Storti Foundation